| MYRIAD GENETICS DL-,01 |
| USA |
| Gesundheit |
| US62855J1043 / 897518 |
| MYD (Frankfurt) / MYGN (NASDAQ) |
| FRA:MYD, ETR:MYD, MYD:GR, NASDAQ:MYGN |
| - |
| https://myriad.com/ |
|
Myriad Genetics Inc. is a biotechnology company specializing in the development and commercialization of genetic tests that assess risk for cancer and other hereditary conditions. The company is renowned for its pioneering efforts in molecular diagno..
>Volltext.. |
| 347.79 Mio. EUR |
| 399.14 Mio. EUR |
| 716.49 Mio. EUR |
| -13.12 Mio. EUR |
| -317.97 Mio. EUR |
| -3.44 EUR |
| 182.32 Mio. EUR |
| 130 Mio. EUR |
| 1.56 Mio. EUR |
| 1.12 |
| -13.24% |
| -153.34% |
| - |
| - |
| - |
| MYRIAD GENETICS |
| 28.03.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|